$NBIX
NEUROCRINE BIOSCIENCES INC

2015 Q4 Form 10-Q Financial Statement

#000119312515358050 Filed on October 29, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.900M $11.50M $4.700M
YoY Change 78.0% 144.68% 46.88%
% of Gross Profit
Research & Development $21.80M $24.39M $12.19M
YoY Change 40.65% 100.0% 28.49%
% of Gross Profit
Depreciation & Amortization $300.0K $200.0K $200.0K
YoY Change 50.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $30.75M $35.84M $16.86M
YoY Change 50.22% 112.64% 32.37%
Operating Profit -$35.84M -$16.86M
YoY Change 112.64% 40.4%
Interest Expense $600.0K $600.0K $200.0K
YoY Change 200.0% 200.0% 100.0%
% of Operating Profit
Other Income/Expense, Net $800.0K $1.409M $982.0K
YoY Change 0.0% 43.48% 12.23%
Pretax Income -$29.30M -$34.40M -$15.90M
YoY Change 51.03% 116.35% 43.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$29.32M -$34.44M -$15.88M
YoY Change 50.77% 116.91% 42.62%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$339.9K -$400.5K -$209.5K
COMMON SHARES
Basic Shares Outstanding 86.20M shares 85.87M shares 75.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $379.2M $376.8M $179.7M
YoY Change 95.67% 109.68% 14.53%
Cash & Equivalents $74.20M $66.38M $29.05M
Short-Term Investments $305.0M $310.5M $150.6M
Other Short-Term Assets $4.883M $5.940M $4.194M
YoY Change 11.13% 41.63% 87.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $384.1M $382.8M $183.9M
YoY Change 93.78% 108.18% 15.48%
LONG-TERM ASSETS
Property, Plant & Equipment $3.432M $2.874M $2.292M
YoY Change 36.9% 25.39% 31.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $82.50M $102.0M $67.10M
YoY Change 120.0% 52.01% 9485.71%
Other Assets $4.800M $4.800M $4.400M
YoY Change 0.0% 9.09% 2.33%
Total Long-Term Assets $90.71M $109.7M $73.88M
YoY Change 102.34% 48.41% 994.73%
TOTAL ASSETS
Total Short-Term Assets $384.1M $382.8M $183.9M
Total Long-Term Assets $90.71M $109.7M $73.88M
Total Assets $474.8M $492.4M $257.8M
YoY Change 95.36% 91.05% 55.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.561M $1.197M $900.0K
YoY Change 941.06% 33.0% -17.96%
Accrued Expenses $19.03M $14.51M $9.307M
YoY Change 65.4% 55.95% 18.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.72M $19.82M $14.05M
YoY Change 64.17% 41.13% 5.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $221.0K $220.0K $260.0K
YoY Change -15.0% -15.38% 71.05%
Total Long-Term Liabilities $221.0K $220.0K $260.0K
YoY Change -15.0% -15.38% 71.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.72M $19.82M $14.05M
Total Long-Term Liabilities $221.0K $220.0K $260.0K
Total Liabilities $50.33M $45.49M $33.71M
YoY Change 46.59% 34.94% -8.07%
SHAREHOLDERS EQUITY
Retained Earnings -$915.2M -$885.9M -$806.9M
YoY Change 10.76% 9.8% 6.85%
Common Stock $1.341B $1.333B $76.00K
YoY Change 29.5% 1754467.11% 13.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $424.5M $446.9M $224.0M
YoY Change
Total Liabilities & Shareholders Equity $474.8M $492.4M $257.8M
YoY Change 95.36% 91.05% 55.3%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$29.32M -$34.44M -$15.88M
YoY Change 50.77% 116.91% 42.62%
Depreciation, Depletion And Amortization $300.0K $200.0K $200.0K
YoY Change 50.0% 0.0% 0.0%
Cash From Operating Activities -$15.20M -$18.60M -$12.10M
YoY Change -0.65% 53.72% 12.04%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$300.0K -$300.0K
YoY Change 100.0% 0.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities $22.90M -$47.60M $3.500M
YoY Change 44.03% -1460.0% -391.67%
Cash From Investing Activities $22.10M -$47.90M $3.200M
YoY Change 42.58% -1596.88% -346.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000M 700.0K 500.0K
YoY Change -41.18% 40.0% -81.48%
NET CHANGE
Cash From Operating Activities -15.20M -18.60M -12.10M
Cash From Investing Activities 22.10M -47.90M 3.200M
Cash From Financing Activities 1.000M 700.0K 500.0K
Net Change In Cash 7.900M -65.80M -8.400M
YoY Change 315.79% 683.33% -10.64%
FREE CASH FLOW
Cash From Operating Activities -$15.20M -$18.60M -$12.10M
Capital Expenditures -$800.0K -$300.0K -$300.0K
Free Cash Flow -$14.40M -$18.30M -$11.80M
YoY Change -3.36% 55.08% 10.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 nbix Cease Use Liability
CeaseUseLiability
2892000
CY2015Q2 nbix Cease Use Liability
CeaseUseLiability
2326000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29046000
CY2014Q3 nbix Cease Use Liability
CeaseUseLiability
2788000
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85884128 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85884128 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19822000
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14514000
CY2015Q3 us-gaap Liabilities
Liabilities
45493000
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
232000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
86000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1333385000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
220000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-609000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-885919000
CY2015Q3 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
15200000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1789000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
446943000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
492436000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1197000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
412453000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4791000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2874000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
382785000
CY2015Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5940000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
248576000
CY2015Q3 us-gaap Investments
Investments
412500000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
667000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66378000
CY2015Q3 us-gaap Assets
Assets
492436000
CY2015Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
101986000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
5590000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
668000
CY2015Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
310467000
CY2015Q3 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2015Q3 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
242986000
CY2015Q3 nbix Cease Use Liability
CeaseUseLiability
2151000
CY2015Q3 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
11761000
CY2015Q3 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
1670000
CY2015Q3 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
481000
CY2015Q3 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3398000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86196628 shares
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789000
CY2013Q4 nbix Cease Use Liability
CeaseUseLiability
3096000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76465942 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76465942 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15664000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11508000
CY2014Q4 us-gaap Liabilities
Liabilities
34334000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
119000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
76000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1035205000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-277000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-826305000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1877000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
208699000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243033000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
246000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
200287000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4831000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2507000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
198203000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4394000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
167462000
CY2014Q4 us-gaap Investments
Investments
200300000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
283000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2014Q4 us-gaap Assets
Assets
243033000
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
37492000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
600000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74050000 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41310000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1173000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2745000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2410000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
241156000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
283000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
162795000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
167462000
CY2014Q4 nbix Cease Use Liability
CeaseUseLiability
2678000
CY2014Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
14322000
CY2014Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2211000
CY2014Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
467000
CY2014Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3324000
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
100000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
900000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2800000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31831000
us-gaap Licenses Revenue
LicensesRevenue
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-43943000
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1471000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
us-gaap Investment Income Net
InvestmentIncomeNet
432000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2845000
us-gaap Net Income Loss
NetIncomeLoss
-41098000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2400000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
136999000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
603000
us-gaap Operating Expenses
OperatingExpenses
43943000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
136999000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
19000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13016000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2151000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15743000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7900000
us-gaap Share Based Compensation
ShareBasedCompensation
7938000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
121373000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-120911000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3800000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30927000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2414000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
308000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-308000
nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
-4000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
NBIX
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
200000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1100000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4000000 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22794000
dei Amendment Flag
AmendmentFlag
false
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1200000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83927000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59946000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1106000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4311000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2496000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
376437000
us-gaap Licenses Revenue
LicensesRevenue
19769000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63454000
us-gaap Revenues
Revenues
19769000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1546000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-40000
us-gaap Investment Income Net
InvestmentIncomeNet
1344000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3840000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
1100000
us-gaap Net Income Loss
NetIncomeLoss
-59614000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-332000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
276024000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
739000
us-gaap Operating Expenses
OperatingExpenses
83223000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
276024000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
25000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23541000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3957000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35364000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22200000
us-gaap Share Based Compensation
ShareBasedCompensation
22166000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
159628000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-217866000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5300000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59682000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-40000
nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
nbix Subleased Agreement Area
SubleasedAgreementArea
30000 sqft
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2487000
nbix Lease Expiration Year
LeaseExpirationYear
2019
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
440000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-527000
nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-87000
nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
9000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-15875000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133200000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2800000 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75948000 shares
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15956000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
0
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16857000
CY2014Q3 us-gaap Revenues
Revenues
0
CY2014Q3 us-gaap Investment Income Net
InvestmentIncomeNet
176000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
982000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
16857000
CY2015Q3 us-gaap Revenues
Revenues
0
CY2015Q3 us-gaap Investment Income Net
InvestmentIncomeNet
581000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1409000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-34435000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-205000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
35844000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11456000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4663000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12194000
CY2014Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
805000
CY2014Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
104000
CY2014Q3 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
CY2014Q3 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
1000
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4200000 shares
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85856000 shares
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34640000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2015Q3 us-gaap Licenses Revenue
LicensesRevenue
0
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35844000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13900000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24388000
CY2015Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
828000
CY2015Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
175000
CY2015Q3 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
CY2015Q3 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
0

Files In Submission

Name View Source Status
0001193125-15-358050-index-headers.html Edgar Link pending
0001193125-15-358050-index.html Edgar Link pending
0001193125-15-358050.txt Edgar Link pending
0001193125-15-358050-xbrl.zip Edgar Link pending
d66788d10q.htm Edgar Link pending
d66788dex311.htm Edgar Link pending
d66788dex312.htm Edgar Link pending
d66788dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nbix-20150930.xml Edgar Link completed
nbix-20150930.xsd Edgar Link pending
nbix-20150930_cal.xml Edgar Link unprocessable
nbix-20150930_def.xml Edgar Link unprocessable
nbix-20150930_lab.xml Edgar Link unprocessable
nbix-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending